Assessment of mutations in KCNN2 and ZNF135 to patient neurological symptoms
Vijeta Raghuram1, Sydney Weber, Jacob Raber
1aVollum Institute bDepartment of Behavioral Neuroscience cDepartment of Obstetrics and Gynecology, Oregon Health and Science University, Portland, Oregon dDepartment of Neurology, Geriatric Research (GRECC), VA Puget Sound Healthcare System, University of Washington, Seattle, Washington, USA.
Abstract:
Exome sequencing from a patient with neurological and developmental symptoms revealed two mutations in separate genes. One was a homozygous transition mutation that results in an in-frame, premature translational stop codon in the ZNF135 gene predicted to encode a transcriptional repressor. Another mutation was heterozygous, a single nucleotide duplication in the KCNN2 gene that encodes a Ca-activated K channel, SK2, and leads to a translational frame shift and a premature stop codon. Heterologous expression studies, brain slice recordings, and coordination tests from a transgenic mouse line carrying the SK2 mutation suggest that it does not contribute to the patient's symptoms. ZNF135 is expressed in human brain and it is likely that the homozygous mutation underlies the human phenotype.
More Related Videos
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
